Inmune Bio Stock Return On Equity
INMB Stock | USD 11.75 0.12 1.03% |
INmune Bio fundamentals help investors to digest information that contributes to INmune Bio's financial success or failures. It also enables traders to predict the movement of INmune Stock. The fundamental analysis module provides a way to measure INmune Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to INmune Bio stock.
The current year's Return On Equity is expected to grow to 0.84. INmune | Return On Equity |
INmune Return On Equity Analysis
INmune Bio's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
More About Return On Equity | All Equity Analysis
INmune Bio Return On Equity |
|
Return On Equity | = | Net IncomeTotal Equity |
Current INmune Bio Return On Equity | -0.51 |
Most of INmune Bio's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, INmune Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
INmune Return On Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for INmune Bio is extremely important. It helps to project a fair market value of INmune Stock properly, considering its historical fundamentals such as Return On Equity. Since INmune Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of INmune Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of INmune Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition |
INmune Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, INmune Bio has a Return On Equity of -0.506. This is 97.89% lower than that of the Biotechnology sector and 98.61% lower than that of the Health Care industry. The return on equity for all United States stocks is 63.23% higher than that of the company.
INmune Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses INmune Bio's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of INmune Bio could also be used in its relative valuation, which is a method of valuing INmune Bio by comparing valuation metrics of similar companies.INmune Bio is currently under evaluation in return on equity category among related companies.
INmune Fundamentals
Return On Equity | -0.51 | ||||
Return On Asset | -0.23 | ||||
Operating Margin | (198.33) % | ||||
Current Valuation | 181.23 M | ||||
Shares Outstanding | 18.02 M | ||||
Shares Owned By Insiders | 34.91 % | ||||
Shares Owned By Institutions | 13.83 % | ||||
Number Of Shares Shorted | 1.44 M | ||||
Price To Earning | (7.51) X | ||||
Price To Book | 4.69 X | ||||
Price To Sales | 935.68 X | ||||
Revenue | (155 K) | ||||
Gross Profit | 374 K | ||||
EBITDA | 30.01 M | ||||
Net Income | (27.43 M) | ||||
Cash And Equivalents | 61.21 M | ||||
Cash Per Share | 3.41 X | ||||
Total Debt | 10.44 M | ||||
Debt To Equity | 0.22 % | ||||
Current Ratio | 30.87 X | ||||
Book Value Per Share | 2.44 X | ||||
Cash Flow From Operations | (22.69 M) | ||||
Short Ratio | 19.61 X | ||||
Earnings Per Share | (1.52) X | ||||
Target Price | 19.67 | ||||
Number Of Employees | 10 | ||||
Beta | 2.0 | ||||
Market Capitalization | 209.59 M | ||||
Total Asset | 57 M | ||||
Retained Earnings | (121.02 M) | ||||
Working Capital | 53.76 M | ||||
Current Asset | 8.38 M | ||||
Current Liabilities | 721.01 K | ||||
Z Score | 11.94 | ||||
Net Asset | 57 M |
About INmune Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze INmune Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of INmune Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of INmune Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported | Projected for 2024 | ||
Return On Equity | 0.80 | 0.84 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out INmune Bio Piotroski F Score and INmune Bio Altman Z Score analysis. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Stocks Directory Find actively traded stocks across global markets |
Is INmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.012 | Quarterly Revenue Growth (0.56) | Return On Assets (0.23) | Return On Equity (0.51) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.